Chemokines and chemokine receptors: potential therapeutic targets in multiple sclerosis

Current Drug Targets. Inflammation and Allergy
Diane M MullerJudith M Greer

Abstract

Multiple sclerosis (MS) is a common inflammatory and demyelinating disease of the central nervous system (CNS), which causes progressive neurological disability. The disease is characterised pathologically by destruction of the myelin sheaths, which surround nerve fibres in the CNS. It is believed that this tissue damage in the brain and spinal cord of MS patients is caused by an inflammatory response that is initiated when autoreactive T cells, specific for myelin antigens, cross the blood-brain barrier and detect their antigen within the CNS. As a result, most therapies to date have been immunosuppressive and/or anti-inflammatory in nature, targeting the processes involved in activation and migration of leukocytes and promotion of the immune response. Over the last decade, a family of chemotactic cytokines called chemokines, have been found to be involved in the trafficking of leukocytes in both the normal and pathological states. The expression of these chemokines and their receptors is increased during the acute phase of MS and also in the animal model of MS, experimental autoimmune encephalomyelitis (EAE). As a result, these chemokines have become an emerging focus for research into novel therapeutics for EAE and ultimatel...Continue Reading

Citations

Feb 3, 2007·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Juliana Croitoru-LamouryBruce J Brew
May 10, 2008·Journal of Veterinary Internal Medicine·T M FanL D Garrett
Aug 2, 2008·PPAR Research·John J BrightSharmistha Chakraborty
Nov 11, 2008·Molecular and Cellular Endocrinology·Malgorzata Burek, Carola Y Förster
Aug 19, 2008·Journal of the Neurological Sciences·Isabell HamannCarmen Infante-Duarte
Sep 9, 2008·Experimental and Molecular Pathology·Yangtai GuanGuang-Xian Zhang
Sep 10, 2005·Journal of Neurochemistry·Romain Daniel GosselinStéphane Melik-Parsadaniantz
Oct 3, 2006·Current Opinion in Immunology·Natalia M Rebenko-MollRichard M Ransohoff
Nov 29, 2005·Trends in Pharmacological Sciences·Eroboghene E UboguRichard M Ransohoff
Jan 22, 2008·Journal of Neuroimmunology·Sergey G KremlevGeorge Tuszynski
Oct 29, 2005·Drug Discovery Today·Bert A 't Hart, Kees Heije
Feb 26, 2005·Journal of Neuroinflammation·Ileana BanisorBernadette Kalman
Jan 15, 2015·Journal of the Neurological Sciences·Piotr Iwanowski, Jacek Losy
Aug 24, 2005·Immunopharmacology and Immunotoxicology·Abbas MirshafieySeiji Miyoshi

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood Brain Barrier Chips

The blood brain barrier (BBB) is comprised of endothelial cells that regulate the influx and outflux of plasma concentrations. Lab-on-a-chip devices allow scientists to model diseases and mechanisms such as the passage of therapeutic antibodies across the BBB. Discover the latest research on BBB chips here.

Blood Brain Barrier Regulation in Health & Disease

The blood brain barrier is essential in regulating the movement of molecules and substances in and out of the brain. Disruption to the blood brain barrier and changes in permeability allow pathogens and inflammatory molecules to cross the barrier and may play a part in the pathogenesis of neurodegenerative disorders. Here is the latest research in this field.

Blood Brain Barrier

The blood brain barrier is a border that separates blood from cerebrospinal fluid. Discover the latest search on this highly selective semipermeable membrane here.